Clinical Trials
14 trialsNCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT03363893 2025-11-12
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
Carrick Therapeutics Limited
Phase 1/2 Completed
NCT03099174 2025-06-24
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT02437318 2025-02-13
SOLAR-1
Novartis
Phase 3 Completed
NCT02422615 2023-11-30
MONALEESA-3
Novartis
Phase 3 Completed
NCT04524728 2020-08-24
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
Istituti Clinici Scientifici Maugeri SpA
Completed
NCT00313170 2020-01-06
FINDER II
AstraZeneca
Phase 2 Completed
NCT00274469 2019-09-06
FIRST
AstraZeneca
Phase 2 Completed
NCT02116803 2018-03-01
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
Novartis
Phase 2/3 Completed
NCT00534417 2013-02-01
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Accelerated Community Oncology Research Network
Phase 2 Completed
NCT00256698 2012-08-01
FACT
AstraZeneca
Phase 3 Completed
NCT01399086 2012-03-13
Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer
Hellenic Oncology Research Group
Completed
NCT00305448 2012-02-15
FINDER I
AstraZeneca
Phase 2 Completed
NCT00357110 2010-12-21
@FAME
AstraZeneca
Phase 2 Completed